Immunovant, Inc. (IMVT) Balance Sheet
IMVT balance sheet, FY2026
March 31, 2026 · U.S. dollars$957.6M assets = $105.0M liabilities + $852.6M equity
Both columns are drawn to the same scale: what IMVT owns equals what it owes plus shareholders’ equity. Hover a block for its value.
IMVT financial health
Descriptive bands, not a rating. Fiscal FY2026.
IMVT balance sheet trends, FY2018–FY2026
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $113,170FY2018 | $957.6MFY2026 | +209.7%/yr | |
| Total liabilities | $1.6MFY2018 | $105.0MFY2026 | +68.6%/yr | |
| Shareholders’ equity | −$1.5MFY2018 | $852.6MFY2026 | — | |
| Cash & short-term investments | $325,000FY2019 | $902.1MFY2026 | +210.4%/yr | |
| Total debt | $300,000FY2019 | $72,000FY2026 | −18.4%/yr | |
| Net cash (debt) | $25,000FY2019 | $902.0MFY2026 | +$902.0M | |
| Working capital | −$1.5MFY2018 | $844.4MFY2026 | +$845.9M | |
| Book value per share | $2.18FY2020 | $4.67FY2026 | +13.6%/yr | |
| Current ratio | 0.07FY2018 | 9.09FY2026 | +9.02 | |
| Debt / equity | 12.22FY2019 | 0.00FY2026 | −12.22 | |
| Shares outstanding | 43.2MFY2020 | 182.4MFY2026 | +27.1%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
IMVT assets
IMVT liabilities and equity
IMVT debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
IMVT balance sheet
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | |
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Cash & short-term investments | $902.1M | $714.0M | $635.4M | $376.5M | $493.8M | $400.1M | $100.6M | $325,000 | — |
| Cash & equivalents | $902.1M | $714.0M | $635.4M | $376.5M | $493.8M | $400.1M | $100.6M | $325,000 | — |
| Receivables | $3.9M | $2.5M | $5.5M | $885,000 | $12.9M | $1.1M | $3.0M | $3.0M | $0 |
| Inventory | $0 | $0 | −$24.9M | $0 | $0 | $0 | $0 | $0 | $0 |
| Other current assets | $42.8M | $51.2M | $49.8M | $26.9M | $6.3M | $7.7M | $5.5M | $0 | $113,170 |
| Total current assets | $948.8M | $767.7M | $665.8M | $404.3M | $512.9M | $409.0M | $109.1M | $325,000 | $113,170 |
| Property, plant & equipment (net) | $515,000 | $942,000 | $595,000 | $1.5M | $2.6M | $3.5M | $65,000 | $54 | $0 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $8.2M | $7.6M | $347,000 | $0 | $0 | $0 | $246,000 | $79,946 | $0 |
| Total assets | $957.6M | $776.2M | $666.7M | $405.8M | $515.6M | $412.5M | $109.4M | $405,000 | $113,170 |
| Liabilities | |||||||||
| Accounts payable | $7.5M | $17.7M | $7.2M | $1.4M | $18.6M | $2.4M | $1.2M | $206 | $1.1M |
| Short-term debt | $72,000 | $98,000 | $138,000 | $1.2M | $1.1M | $1.2M | $3.2M | $300,000 | — |
| Deferred revenue | — | — | −$26.7M | — | — | — | −$3.2M | −$206 | — |
| Total current liabilities | $104.4M | $68.8M | $48.6M | $43.3M | $44.5M | $18.8M | $15.3M | $380,448 | $1.6M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | $72,000 | $98,000 | $138,000 | $1.2M | $2.4M | $3.4M | $0 | — | — |
| Other long-term liabilities | $552,999 | $1.1M | $347,000 | $47,000 | $1.2M | $2.2M | $14.1M | $300,000 | $0 |
| Total liabilities | $105.0M | $68.8M | $49.0M | $43.3M | $45.7M | $21.0M | $15.3M | $380,448 | $1.6M |
| Shareholders' equity | |||||||||
| Common stock & paid-in capital | $20,000 | $16,000 | $14,000 | $13,000 | $12,000 | $10,000 | $5,000 | $288 | — |
| Retained earnings (deficit) | −$1.75B | −$1.24B | −$825.7M | −$566.3M | −$355.4M | −$198.7M | −$91.2M | −$448 | — |
| Accumulated other comprehensive income | $730,000 | $1.5M | $1.9M | $852,000 | $404,000 | −$298,000 | −$16,000 | $343,000 | −$1.5M |
| Total shareholders' equity | $852.6M | $707.4M | $617.8M | $362.5M | $469.8M | $391.5M | $94.1M | $24,552 | −$1.5M |
| Key figures | |||||||||
| Total debt | $72,000 | $98,000 | $138,000 | $1.2M | $2.4M | $3.4M | $3.2M | $300,000 | — |
| Net cash (debt) | $902.0M | $713.9M | $635.2M | $375.3M | $491.5M | $396.7M | $97.4M | $25,000 | — |
| Working capital | $844.4M | $698.9M | $617.2M | $361.0M | $468.4M | $390.2M | $93.8M | −$55,448 | −$1.5M |
| Tangible book value | $852.6M | $707.4M | $617.8M | $362.5M | $469.8M | $391.5M | $94.1M | $24,552 | −$1.5M |
| Book value per share | $4.67 | $4.67 | $4.47 | $2.95 | $4.28 | $4.46 | $2.18 | — | — |
| Shares outstanding | 182.4M | 151.6M | 138.1M | 123.1M | 109.7M | 87.8M | 43.2M | — | — |
| Current ratio | 9.09 | 11.16 | 13.70 | 9.34 | 11.52 | 21.79 | 7.12 | 0.85 | 0.07 |
| Quick ratio | 8.68 | 10.42 | 13.18 | 8.72 | 11.38 | 21.38 | 6.76 | 8.64 | 0.00 |
| Debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.03 | 12.22 | — |
| Equity / assets | 89.0% | 91.1% | 92.7% | 89.3% | 91.1% | 94.9% | 86.0% | 6.1% | −1,322.5% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $797.8M | $902.1M | $994.5M | $521.9M | $598.9M | $714.0M | $374.7M | $472.9M | $560.0M | $635.4M | $690.9M | $269.9M |
| Cash & equivalents | $797.8M | $902.1M | $994.5M | $521.9M | $598.9M | $714.0M | $374.7M | $472.9M | $560.0M | $635.4M | $690.9M | $269.9M |
| Receivables | $697,000 | $3.9M | $1.6M | $2.0M | $1.9M | $2.5M | $2.2M | $1.9M | $2.4M | $5.5M | $1.0M | $1.4M |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1 | $0 |
| Other current assets | $52.7M | $42.8M | $46.8M | $49.7M | $50.9M | $51.2M | $35.6M | $32.6M | $26.6M | $24.9M | $18.8M | $19.8M |
| Total current assets | $851.2M | $948.8M | $1.04B | $573.5M | $651.8M | $767.7M | $412.5M | $507.4M | $589.0M | $665.8M | $710.8M | $291.2M |
| Property, plant & equipment (net) | $351,000 | $515,000 | $531,000 | $632,000 | $737,000 | $942,000 | $774,000 | $716,000 | $631,000 | $595,000 | $670,000 | $893,000 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $961,000 | $7.7M | $8.9M | $8.8M | $8.9M | $7.6M | $7.6M | $7.6M | $0 | $347,000 | $0 | $0 |
| Total assets | $852.5M | $957.0M | $1.05B | $583.0M | $661.4M | $776.2M | $420.9M | $515.7M | $589.7M | $666.7M | $711.4M | $292.1M |
| Liabilities | ||||||||||||
| Accounts payable | $10.1M | $7.5M | $8.6M | $6.9M | $7.8M | $17.7M | $19.8M | $20.7M | $11.0M | $7.2M | $3.9M | $7.5M |
| Short-term debt | — | $72,000 | — | — | — | $98,000 | $23,000 | $47,000 | $69,000 | $138,000 | $306,000 | $614,000 |
| Total current liabilities | $117.1M | $104.4M | $66.3M | $63.3M | $52.9M | $68.8M | $68.3M | $66.7M | $45.0M | $48.6M | $32.1M | $40.3M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Lease obligations | — | $72,000 | — | — | — | $98,000 | $23,000 | $47,000 | $69,000 | $138,000 | $306,000 | $614,000 |
| Other long-term liabilities | $0 | $0 | $0 | $0 | $0 | $1.1M | $0 | $0 | $0 | $347,000 | $0 | $0 |
| Total liabilities | $117.1M | $104.4M | $66.3M | $63.3M | $52.9M | $68.8M | $68.3M | $66.7M | $45.0M | $49.0M | $32.1M | $40.3M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $20,000 | $20,000 | $20,000 | $17,000 | $16,000 | $16,000 | $14,000 | $14,000 | $14,000 | $14,000 | $14,000 | $13,000 |
| Retained earnings (deficit) | −$1.90B | −$1.75B | −$1.60B | −$1.49B | −$1.36B | −$1.24B | −$1.13B | −$1.02B | −$912.8M | −$825.7M | −$750.4M | −$698.9M |
| Accumulated other comprehensive income | $725,000 | $730,000 | $1.2M | $1.4M | $1.7M | $1.5M | $2.5M | $1.9M | $1.8M | $1.9M | −$600,000 | $513,000 |
| Total shareholders' equity | $735.4M | $852.6M | $986.1M | $519.7M | $608.5M | $707.4M | $352.6M | $449.1M | $544.7M | $617.8M | $679.3M | $251.8M |
| Key figures | ||||||||||||
| Total debt | — | $72,000 | — | — | — | $98,000 | $23,000 | $47,000 | $69,000 | $138,000 | $306,000 | $614,000 |
| Net cash (debt) | — | $902.0M | — | — | — | $713.9M | $374.7M | $472.9M | $559.9M | $635.2M | $690.6M | $269.3M |
| Working capital | $734.1M | $844.4M | $976.7M | $510.3M | $598.9M | $698.9M | $344.2M | $440.7M | $544.0M | $617.2M | $678.7M | $250.9M |
| Tangible book value | $735.4M | $852.6M | $986.1M | $519.7M | $608.5M | $707.4M | $352.6M | $449.1M | $544.7M | $617.8M | $679.3M | $251.8M |
| Book value per share | $3.58 | $4.19 | $5.43 | $2.99 | $3.56 | $4.67 | $2.40 | $3.07 | $3.73 | $4.25 | $4.70 | $1.92 |
| Shares outstanding | 205.5M | 203.7M | 181.5M | 173.6M | 170.9M | 151.6M | 146.9M | 146.5M | 146.1M | 145.4M | 144.5M | 131.2M |
| Current ratio | 7.27 | 9.09 | 15.74 | 9.07 | 12.32 | 11.16 | 6.04 | 7.61 | 13.08 | 13.70 | 22.14 | 7.23 |
| Quick ratio | 6.82 | 8.68 | 15.03 | 8.28 | 11.36 | 10.42 | 5.52 | 7.12 | 12.49 | 13.18 | 21.56 | 6.74 |
| Debt / equity | — | 0.00 | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Equity / assets | 86.3% | 89.1% | 93.7% | 89.1% | 92.0% | 91.1% | 83.8% | 87.1% | 92.4% | 92.7% | 95.5% | 86.2% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed May 20, 2026); data from EODHD.
IMVT financial position
At the end of fiscal 2026 (March 31, 2026), Immunovant had total assets of $957.6 million (up 23.4% from a year earlier), total liabilities of $105.0 million and shareholders' equity of $852.6 million. It held $902.1 million in cash and short-term investments against $0.1 million of debt, a net cash position of $902.0 million. Its current ratio was 9.09. In the latest quarter (ended June 30, 2026) total assets were $852.5 million and equity $735.4 million.
Related: IMVT income statement, IMVT cash flow statement, IMVT key metrics. See the IMVT stock overview for the latest quote and news.
IMVT balance sheet FAQ
What are Immunovant's total assets?
Immunovant reported total assets of $957.6 million at the end of fiscal 2026 (March 31, 2026), compared with $776.2 million a year earlier.
How much debt does Immunovant have?
Immunovant had $0.1 million of total debt at the end of fiscal 2026, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.00.
How much cash does Immunovant have?
Immunovant held $902.1 million in cash and short-term investments at the end of fiscal 2026; with $0.1 million of debt that is net cash of $902.0 million.
What is Immunovant's book value?
Immunovant's shareholders' equity (book value) was $852.6 million at the end of fiscal 2026, or $4.67 per share.
What is Immunovant's current ratio?
Immunovant had current assets of $948.8 million and current liabilities of $104.4 million, a current ratio of 9.09 (it can cover its short-term obligations).